In the current study, we aimed to investigate the mechanistic role of DJ-1/PI3K/Akt survival pathway in ischemia/reperfusion (I/R) induced cerebral damage and to investigate if the Resveratrol (RES) mediates its ischemic neuroprotection through this pathway. RES administration to sham rats, boosted GSH level and SOD activity and downregulated iNOS expression without affecting redox levels of DJ-1 forms nor components of PI3K/Akt pathway including PTEN, p-Akt or p/p-GSK3b. However, RES pre-administration to I/R rats, reduced infarction area, oxidative stress, inflammation and apoptosis. Concomitantly, RES ameliorated the decreased levels of oxidized forms of DJ-1 and enhancing its reduction, increased the nuclear protein expression of Nfr-2 and led to activation of PI3K/Akt survival pathway. In conclusion, overoxidation of DJ-1 is a major factor that contributes to post I/R cerebral damage andits reduction by RES could explain the neuroprotection offered by RSE.

To measure tissue levels of bisphenol A (BPA) in uterine leiomyoma (ULM), adjacent myometrium (Myo-F), and normal myometrium (Myo-N). Also, we tested the effect of BPA treatment on rat myometrium. Methods: Uterine leiomyomas and Myo-F tissues were isolated from hysterectomy specimens done to treat symptomatic ULMs (N ¼ 30). Normal myometrium is isolated from hysterectomies done on ULM-free uteri for other benign indications (N ¼ 25). Bisphenol A was measured in 1 g of tissue using solid-phase extraction and high-performance liquid chromatography, with fluorescence detectors. Experimentally, adult female rats were fed BPA orally at a dose of 50 mg/kg/d for 90 days. Animals were killed, and their myometrial thickness and proliferating cell nuclear antigen (PCNA) immunostaining were evaluated. Results: Tissue concentration of BPA in each of ULM (12.3 + 2.8 mg/g) and Myo-F (10.1 + 0.2 mg/g) was significantly higher than that of Myo-N (0.58 + 0.2 mg/g). There was no statistically significant difference in BPA level between ULM and Myo-F within submucous or interstitial/subserous fibroid groups. Compared to control rats, BPA-treated animals showed significantly higher myometrial thickness (168.67+5.7 mm and 281.6+ 20.32 mm, respectively, P ¼ .003) and increased myometrial PCNA immunoscores (1.5 + 0.37 and 10.38 + 0.67, respectively, P  .001). Conclusion: Bisphenol A concentrates in human ULM tissue and its adjacent Myo-F compared to Myo-N. No significant difference is detected in BPA content of ULM tissue of different subtypes. Bisphenol A increases thickness and induces cellular proliferation in rat myometrium. Taken together, our results support a role of BPA in ULM development/growth.

To measure tissue levels of bisphenol A (BPA) in uterine leiomyoma (ULM), adjacent myometrium (Myo-F), and normal myometrium (Myo-N). Also, we tested the effect of BPA treatment on rat myometrium. Methods: Uterine leiomyomas and Myo-F tissues were isolated from hysterectomy specimens done to treat symptomatic ULMs (N ¼ 30). Normal myometrium is isolated from hysterectomies done on ULM-free uteri for other benign indications (N ¼ 25). Bisphenol A was measured in 1 g of tissue using solid-phase extraction and high-performance liquid chromatography, with fluorescence detectors. Experimentally, adult female rats were fed BPA orally at a dose of 50 mg/kg/d for 90 days. Animals were killed, and their myometrial thickness and proliferating cell nuclear antigen (PCNA) immunostaining were evaluated. Results: Tissue concentration of BPA in each of ULM (12.3 + 2.8 mg/g) and Myo-F (10.1 + 0.2 mg/g) was significantly higher than that of Myo-N (0.58 + 0.2 mg/g). There was no statistically significant difference in BPA level between ULM and Myo-F within submucous or interstitial/subserous fibroid groups. Compared to control rats, BPA-treated animals showed significantly higher myometrial thickness (168.67+5.7 mm and 281.6+ 20.32 mm, respectively, P ¼ .003) and increased myometrial PCNA immunoscores (1.5 + 0.37 and 10.38 + 0.67, respectively, P  .001). Conclusion: Bisphenol A concentrates in human ULM tissue and its adjacent Myo-F compared to Myo-N. No significant difference is detected in BPA content of ULM tissue of different subtypes. Bisphenol A increases thickness and induces cellular proliferation in rat myometrium. Taken together, our results support a role of BPA in ULM development/growth.

To measure tissue levels of bisphenol A (BPA) in uterine leiomyoma (ULM), adjacent myometrium (Myo-F), and normal myometrium (Myo-N). Also, we tested the effect of BPA treatment on rat myometrium. Methods: Uterine leiomyomas and Myo-F tissues were isolated from hysterectomy specimens done to treat symptomatic ULMs (N ¼ 30). Normal myometrium is isolated from hysterectomies done on ULM-free uteri for other benign indications (N ¼ 25). Bisphenol A was measured in 1 g of tissue using solid-phase extraction and high-performance liquid chromatography, with fluorescence detectors. Experimentally, adult female rats were fed BPA orally at a dose of 50 mg/kg/d for 90 days. Animals were killed, and their myometrial thickness and proliferating cell nuclear antigen (PCNA) immunostaining were evaluated. Results: Tissue concentration of BPA in each of ULM (12.3 + 2.8 mg/g) and Myo-F (10.1 + 0.2 mg/g) was significantly higher than that of Myo-N (0.58 + 0.2 mg/g). There was no statistically significant difference in BPA level between ULM and Myo-F within submucous or interstitial/subserous fibroid groups. Compared to control rats, BPA-treated animals showed significantly higher myometrial thickness (168.67+5.7 mm and 281.6+ 20.32 mm, respectively, P ¼ .003) and increased myometrial PCNA immunoscores (1.5 + 0.37 and 10.38 + 0.67, respectively, P  .001). Conclusion: Bisphenol A concentrates in human ULM tissue and its adjacent Myo-F compared to Myo-N. No significant difference is detected in BPA content of ULM tissue of different subtypes. Bisphenol A increases thickness and induces cellular proliferation in rat myometrium. Taken together, our results support a role of BPA in ULM development/growth.

To measure tissue levels of bisphenol A (BPA) in uterine leiomyoma (ULM), adjacent myometrium (Myo-F), and normal myometrium (Myo-N). Also, we tested the effect of BPA treatment on rat myometrium. Methods: Uterine leiomyomas and Myo-F tissues were isolated from hysterectomy specimens done to treat symptomatic ULMs (N ¼ 30). Normal myometrium is isolated from hysterectomies done on ULM-free uteri for other benign indications (N ¼ 25). Bisphenol A was measured in 1 g of tissue using solid-phase extraction and high-performance liquid chromatography, with fluorescence detectors. Experimentally, adult female rats were fed BPA orally at a dose of 50 mg/kg/d for 90 days. Animals were killed, and their myometrial thickness and proliferating cell nuclear antigen (PCNA) immunostaining were evaluated. Results: Tissue concentration of BPA in each of ULM (12.3 + 2.8 mg/g) and Myo-F (10.1 + 0.2 mg/g) was significantly higher than that of Myo-N (0.58 + 0.2 mg/g). There was no statistically significant difference in BPA level between ULM and Myo-F within submucous or interstitial/subserous fibroid groups. Compared to control rats, BPA-treated animals showed significantly higher myometrial thickness (168.67+5.7 mm and 281.6+ 20.32 mm, respectively, P ¼ .003) and increased myometrial PCNA immunoscores (1.5 + 0.37 and 10.38 + 0.67, respectively, P  .001). Conclusion: Bisphenol A concentrates in human ULM tissue and its adjacent Myo-F compared to Myo-N. No significant difference is detected in BPA content of ULM tissue of different subtypes. Bisphenol A increases thickness and induces cellular proliferation in rat myometrium. Taken together, our results support a role of BPA in ULM development/growth.

To measure tissue levels of bisphenol A (BPA) in uterine leiomyoma (ULM), adjacent myometrium (Myo-F), and normal myometrium (Myo-N). Also, we tested the effect of BPA treatment on rat myometrium. Methods: Uterine leiomyomas and Myo-F tissues were isolated from hysterectomy specimens done to treat symptomatic ULMs (N ¼ 30). Normal myometrium is isolated from hysterectomies done on ULM-free uteri for other benign indications (N ¼ 25). Bisphenol A was measured in 1 g of tissue using solid-phase extraction and high-performance liquid chromatography, with fluorescence detectors. Experimentally, adult female rats were fed BPA orally at a dose of 50 mg/kg/d for 90 days. Animals were killed, and their myometrial thickness and proliferating cell nuclear antigen (PCNA) immunostaining were evaluated. Results: Tissue concentration of BPA in each of ULM (12.3 + 2.8 mg/g) and Myo-F (10.1 + 0.2 mg/g) was significantly higher than that of Myo-N (0.58 + 0.2 mg/g). There was no statistically significant difference in BPA level between ULM and Myo-F within submucous or interstitial/subserous fibroid groups. Compared to control rats, BPA-treated animals showed significantly higher myometrial thickness (168.67+5.7 mm and 281.6+ 20.32 mm, respectively, P ¼ .003) and increased myometrial PCNA immunoscores (1.5 + 0.37 and 10.38 + 0.67, respectively, P  .001). Conclusion: Bisphenol A concentrates in human ULM tissue and its adjacent Myo-F compared to Myo-N. No significant difference is detected in BPA content of ULM tissue of different subtypes. Bisphenol A increases thickness and induces cellular proliferation in rat myometrium. Taken together, our results support a role of BPA in ULM development/growth.

NULL

NULL

NULL

NULL